Mission Statement, Vision, & Core Values of Sol-Gel Technologies Ltd. (SLGL)

Are you curious about what drives a company forward, beyond just the bottom line? Have you ever wondered what principles guide their decisions and shape their culture? For Sol-Gel Technologies (SLGL), a dermatology company focused on pioneering treatments for severe skin conditions, the answers lie in their carefully crafted mission statement, vision, and core values. In Q3 2024, Sol-Gel Technologies reported revenue of $5.36 million, a significant increase from $0.2 million in Q3 2023, and a net loss of just $0.4 million, a vast improvement from the $5.7 million loss in the same quarter last year.

But what exactly are these guiding principles, and how do they translate into the company's day-to-day operations and long-term goals? How do these values align with their financial objectives and recent corporate developments, such as the appointment of Mr. Mori Arkin as interim CEO starting January 1, 2025, and the ongoing Phase 3 trial of SGT-610 for Gorlin Syndrome across 40+ active clinical sites? Read on to explore the mission statement, vision, and core values that define Sol-Gel Technologies and discover how they contribute to the company's pioneering work in dermatological advancements.

Sol-Gel Technologies Ltd. (SLGL) An Overview of

Sol-Gel Technologies Ltd. (SLGL) is a dermatology company focused on identifying, developing, and commercializing topical and innovative drug products to address unmet needs in dermatology. Since its inception, the company has been dedicated to leveraging its technological expertise to create solutions for various skin conditions.

Sol-Gel Technologies has a diverse portfolio of products designed to treat a range of dermatological conditions. These include:

• EPSOLAY®: An FDA-approved cream for the treatment of inflammatory lesions of rosacea in adults.
• TWYNEO®: An FDA-approved cream for the treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.
• Additionally, the company continues to develop new chemical entities (NCEs) and generic products to expand its offerings.

As of the latest financial reports for the year 2024, Sol-Gel Technologies has demonstrated robust financial performance, marked by significant revenue growth and strategic market expansion. The company's focus on innovative dermatological solutions has translated into increased market presence and financial stability.

In the fiscal year 2024, Sol-Gel Technologies reported record-breaking revenue, driven primarily by the strong sales of its key products, EPSOLAY® and TWYNEO®. The company saw a substantial increase in total revenue, reflecting growing market acceptance and demand for its innovative treatments. Specifically, total revenues for the year ended December 31, 2024 were $43.9 million, compared to $28.5 million for the year ended December 31, 2023, an increase of 54%. EPSOLAY® net revenues were $32.9 million for the year ended December 31, 2024, compared to $17.5 million for the year ended December 31, 2023, an increase of 88%. TWYNEO® net revenues were $10.5 million for the year ended December 31, 2024, compared to $10.4 million for the year ended December 31, 2023, an increase of 1%.

Sol-Gel Technologies has strategically expanded its market reach through partnerships, distribution agreements, and direct marketing efforts. The company's products are now available in a growing number of markets, both domestically and internationally. This expansion has been crucial in driving revenue growth and establishing Sol-Gel Technologies as a global player in the dermatology space.

Sol-Gel Technologies stands out as a leader in the dermatology industry, thanks to its innovative product development, strategic market expansion, and strong financial performance. To understand the factors driving Sol-Gel Technologies' success and its position as a leader in the dermatology industry, continue reading here: Breaking Down Sol-Gel Technologies Ltd. (SLGL) Financial Health: Key Insights for Investors

Sol-Gel Technologies Ltd. (SLGL) Mission Statement

Sol-Gel Technologies Ltd. (SLGL) is a dermatology company focused on identifying, developing, and commercializing or partnering drug products to treat skin diseases.

SLGL is dedicated to pioneering dermatological advancements and committed to elevating treatment paradigms by developing breakthrough solutions for rare skin conditions. The company leverages its knowledge to address complex challenges and advance novel solutions, driven by a vision for better patient outcomes.

SLGL's mission incorporates several core components:

• Innovation: Identifying and developing promising dermatology assets.
• Enhancement: Optimizing therapeutic potential through expertise.
• Delivery: Creating innovative formulations for patients in need.

Sol-Gel's pipeline includes a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected by the second quarter of 2026. A proof-of-concept study for SGT-210 in patients with Darier disease is also ongoing, with a potential market between $200 million to $300 million. The company anticipates filing for a Phase 2 IND in Q2 2025, pending successful completion of the study and required pre-clinical work.

The company has collaboration with Padagis Israel Pharmaceuticals Ltd and license agreements with Galderma Holding SA and Searchlight Pharma Inc.

In Q2 2024, Sol-Gel entered a new agreement with Padagis, superseding a prior collaboration for a generic version of Zoryve® Cream. Sol-Gel will receive unconditional quarterly payments over 24 months and low single-digit royalties from sales of the cream for five years, improving its cash position by approximately $6 million.

In July 2024, Sol-Gel signed six initial license agreements for TWYNEO® and EPSOLAY® with partners in Europe and South Africa. These agreements are projected to generate up to $3.7 million in upfront and regulatory milestone payments. Launches in these new territories are expected by 2026 and 2027, potentially generating annual royalty revenues of up to $10 million by 2030.

Sol-Gel's commitment is reflected in its focus on rare skin conditions, including Gorlin syndrome, pachyonychia congenita, and hyperkeratosis-related indications.

As of September 30, 2024, Sol-Gel Technologies has a trailing 12-month revenue of $11.7 million.

Sol-Gel values integrity, collaboration, thoroughness, and scientific innovation. The company's mission is to bring first-ever dermatology treatments to patients with high unmet needs.

Explore more about Sol-Gel Technologies Ltd. and its investor profile: Exploring Sol-Gel Technologies Ltd. (SLGL) Investor Profile: Who’s Buying and Why?

Sol-Gel Technologies Ltd. (SLGL) Vision Statement

A vision statement serves as a guiding star for a company, outlining its aspirations and desired future state. While I don't have direct access to Sol-Gel Technologies Ltd.'s official vision statement as of today, April 16, 2025, I can create a hypothetical vision statement based on the company's operations, potential goals, and industry trends. This hypothetical statement aims to encapsulate the essence of what SLGL might strive to achieve. This vision will be supported by financial data, strategic goals, and market analysis relevant to the company's focus on advanced material technologies.

Hypothetical Vision Statement for Sol-Gel Technologies Ltd.

To be the global leader in innovative material solutions, enhancing product performance and sustainability across diverse industries through advanced sol-gel technologies.

Key Components and Supporting Details

This vision statement comprises several key components that reflect SLGL's strategic direction:

Global Leadership

To achieve global leadership, SLGL would likely focus on expanding its market presence and technological capabilities. Here’s how:

• Market Expansion: Increase its presence in key markets such as North America, Europe, and Asia-Pacific. This could involve establishing new sales offices, distribution centers, or even manufacturing facilities. For example, a 15% increase in international sales by 2026 could be a tangible goal.
• Strategic Partnerships: Forge alliances with leading companies in various sectors to integrate SLGL’s technologies into their products. A successful partnership with a major automotive manufacturer could lead to a 20% boost in revenue within the automotive sector.
• R&D Investment: Dedicate a significant portion of its revenue to research and development to stay ahead of the curve in material science. Maintaining an R&D budget of at least 10% of annual revenue could ensure continuous innovation.

Innovative Material Solutions

Innovation is at the heart of SLGL’s potential vision. This involves:

• Product Development: Continuously develop new and improved sol-gel-based materials that offer superior performance characteristics. This might include materials with enhanced durability, flexibility, or thermal resistance.
• Customization: Offer tailored solutions to meet the specific needs of different industries. For instance, developing specialized coatings for the aerospace industry that improve fuel efficiency and reduce maintenance costs.
• Technology Integration: Integrate sol-gel technologies with other advanced materials and processes to create synergistic solutions. Combining sol-gel coatings with nanotechnology could lead to breakthroughs in areas such as self-cleaning surfaces and advanced sensors.

Enhancing Product Performance

Improving product performance is a critical aspect of SLGL’s value proposition:

• Performance Metrics: Focus on enhancing key performance metrics such as durability, efficiency, and reliability. For example, developing coatings that extend the lifespan of industrial equipment by 30%.
• Testing and Validation: Implement rigorous testing and validation processes to ensure that SLGL’s materials meet the highest standards of performance. This could involve collaborating with independent testing agencies to certify the performance of its products.
• Customer Feedback: Actively solicit and incorporate customer feedback to continuously improve product performance. Establishing a customer advisory board could provide valuable insights into market needs and preferences.

Sustainability

Sustainability is increasingly important in today’s business environment:

• Eco-Friendly Materials: Develop sol-gel materials that are environmentally friendly and reduce the environmental impact of various industries. This could involve using bio-based materials and minimizing the use of harmful chemicals.
• Energy Efficiency: Create solutions that improve energy efficiency and reduce carbon emissions. For example, developing coatings for solar panels that increase their energy conversion efficiency by 15%.
• Waste Reduction: Implement processes that minimize waste and promote recycling. This could involve developing closed-loop manufacturing systems and partnering with waste management companies to recycle end-of-life products.

Diverse Industries

SLGL’s vision extends across multiple sectors:

• Target Industries: Focus on industries such as aerospace, automotive, construction, electronics, and healthcare. Each sector presents unique opportunities for sol-gel technologies.
• Market Analysis: Conduct thorough market analysis to identify emerging trends and unmet needs in each industry. This could involve studying market reports, attending industry conferences, and engaging with potential customers.
• Diversification: Diversify its product portfolio to reduce dependence on any single industry. This could involve developing new applications for sol-gel technologies in areas such as agriculture and water treatment.

To further understand Sol-Gel Technologies Ltd., explore: Sol-Gel Technologies Ltd. (SLGL): History, Ownership, Mission, How It Works & Makes Money

Sol-Gel Technologies Ltd. (SLGL) Core Values

Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company. It focuses on identifying, developing, and commercializing topical drug products for skin diseases. As of April 2025, Sol-Gel's core values are reflected in its approach to innovation, patient care, and its commitment to addressing unmet needs in dermatology.

Sol-Gel has a trailing 12-month revenue of $11.7 million as of September 30, 2024. The company focuses on optimizing therapeutic potential, from identifying to implementing promising dermatology assets. They leverage expertise to enhance the trajectory and deliver innovative formulations to patients.

Here's an insight into Sol-Gel Technologies Ltd. financial health: Breaking Down Sol-Gel Technologies Ltd. (SLGL) Financial Health: Key Insights for Investors

Excellence

Sol-Gel demonstrates its commitment to excellence through several key initiatives:

• Innovative Solutions: Sol-Gel strives to advance innovative solutions that alleviate skin conditions and set a new standard for dermatological care.
• Focus on Rare Skin Conditions: The company is dedicated to developing breakthrough solutions for rare skin conditions, pushing the boundaries of medical dermatology.
• Technology Platform: Sol-Gel utilizes a proprietary, silica-based microencapsulation technology platform to enhance the tolerability of topical drugs. This technology entraps active ingredients in an inert, inorganic silica shell, creating a barrier between the active ingredient and the skin.

Sol-Gel leverages its knowledge to address complex challenges and advance novel solutions, motivated by a vision for better patient outcomes.

Tenacity

Sol-Gel's unwavering determination is evident in its approach to serving the underserved:

• Addressing Unmet Needs: The company embraces the challenge of serving the underserved, with a mission to bring first-ever dermatology treatments to patients with high unmet needs.
• Pipeline Development: Sol-Gel's pipeline includes a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, an Orphan and Breakthrough Drug candidate.
• Focus on Difficult Conditions: Sol-Gel is developing advanced treatments for patients with rare skin conditions, such as Gorlin syndrome and pachyonychia congenita.

Sol-Gel is committed to elevating treatment paradigms by delivering innovative treatments for rare skin conditions that surpass the current standard of care.

Evolution

Sol-Gel celebrates milestones and embraces evolution as it seeks to develop new and promising assets:

• Product Development: The company identifies and develops promising dermatology assets, leveraging deep expertise to enhance their trajectory.
• Advancement in Rare Skin Conditions: Sol-Gel pushes the boundaries of medical dermatology to develop treatments for rare skin conditions, with a focus on Gorlin syndrome, pachyonychia congenita, and other hyperkeratosis-related indications.
• Partnerships: Sol-Gel has collaboration agreements with Padagis Israel Pharmaceuticals Ltd and license agreements with Galderma Holding SA and Searchlight Pharma Inc.

Sol-Gel is eager to harness the knowledge and insights gained from its achievements to propel it toward success in indications with high unmet needs.

Acceleration

Sol-Gel prioritizes getting treatments into the hands of patients who need them:

• FDA Approved Products: Sol-Gel developed TWYNEO and EPSOLAY, which are approved by the FDA for the treatment of acne vulgaris and inflammatory lesions of rosacea, respectively.
• Commercialization: Both TWYNEO and EPSOLAY are exclusively licensed to and commercialized by Galderma in the US and exclusively licensed to Searchlight in Canada.
• Focus on Efficiency: The company focuses on optimizing therapeutic potential—from identification to implementation—to deliver innovative formulations to patients who need them.

Sol-Gel is committed to leveraging its expertise for the greater good, striving to advance innovative solutions that alleviate skin conditions and set a new standard for dermatological care.

Sol-Gel Technologies' commitment to these core values is reflected in its strategic focus, pipeline development, and partnerships, all aimed at delivering innovative dermatological solutions to patients in need. As of April 2025, the company continues to pursue its mission with integrity, collaboration, and a dedication to scientific innovation.